Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05439278 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05439278 · ClinicalTrials.gov record · last posted 2025-05-21

Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

StatusRecruiting
PhasePhase 3
Started2025-02-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
In newly diagnosed glioblastoma patients aged 70 years or older who are suitable for concurrent temozolomide, the optimal dose of radiation therapy is controversial . The purpose of this study is to compare conventional radiotherapy of 60 Gy (6 weeks) versus hypofractionated radiotherapy of 40 Gy (3 weeks) in terms of overall survival as the primary endpoint along with progression-free survival, toxicity, quality of life, and prognostic biomarkers.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2022-06-27. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-05-15
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT05439278
Lead Sponsor Severance Hospital
Conditions Glioblastoma
Enrollment 178 participants
Start Date 2025-02-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-21